George Yancopoulos | |
|---|---|
 | |
| Born | 1959 (age 64–65) |
| Education | Columbia University (BA, MD, PhD) |
| Occupation | Biomedical scientist |
| Employer | Regeneron |
George D. Yancopoulos (born 1959) is a Greek-American biomedical scientist who is the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals.[1]
Yancopoulos is a member of the National Academy of Sciences, and the holder of more than 100 patents.[2] He is a principal inventor and developer of Regeneron's ten FDA-approved or -authorized treatments, as well as of Regeneron's foundational technologies for target and drug development, such as its proprietary TRAP technology, and the VelociGene and VelocImmune antibody technologies.[3][4]
- ^ "Exclusive: Biotech Regeneron on verge of big leagues". Reuters. May 12, 2010. Archived from the original on March 5, 2016. Retrieved May 1, 2011.
- ^ "George Yancopoulos". United States Patent and Trademark Office. Retrieved July 25, 2018.
- ^ Toni Nasr (February 5, 2018). "Regeneron Investment: Healthcare With Wealthcare". Seeking Alpha.
- ^ "Our Team". Regeneron Pharmaceuticals. Retrieved July 26, 2018.